ConsortiumConsortium
consortium teaser

QuicklinksQuicklinks
Download of information and forms Download of information and forms Educational tools for parents Educational tools for parents Educational tools for clinicians and health care professionals Educational tools for clinicians and health care professionals Coordinator/Project Office Coordinator/Project Office

NEMO SurveyNEMO Survey

Please click here to participate in the European survey on management (including diagnosis and treatment) of neonatal seizures.


NEMO NewsletterNEMO Newsletter

Please click here

to read the 4th NEMO Newsletter.

Please click here

to read the 3rd NEMO Newsletter.

Please click here
to read the 2nd NEMO Newsletter.


NEMO project flyerNEMO project flyer

       

  Please click here
  to download the flyer.






SEVENTH FRAMEWORK PROGRAMME


Objectives of NEMO

 Primary objectives

  • To find the optimal dose of bumetanide when given as addition to standard therapy (phenobarbitone) for seizures in full term babies with hypoxic ischemic encephalopathy.
  • To assess the efficacy and safety of bumetanide for the treatment of neonatal seizures in babies with hypoxic ischaemic encephalopathy which are not controlled by phenobarbitone.
  • To develop and adapt a bumetanide formulation suitable for newborns with seizures and to apply for a Paediatric Use Marketing Authorization (PUMA).

Secondary objectives

  • To assess pharmacokinetics and pharmacodynamics of bumetanide in neonatal seizure treatment.
  • To assess whether successful treatment of neonatal seizures will improve long-term neuro-developmental outcome in babies with HIE at the age of 24 months.
  • To further evaluate the mechanisms of action for bumetanide in the immature brain.

Objectives of NEMO